Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
Avtorji:ID Vrankar, Martina (Avtor)
ID Kern, Izidor, Klinika Golnik (Avtor)
ID Stanič, Karmen (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (822,12 KB)
MD5: 32B12D04B07A172A730190F4FA21CDBD
 
URL URL - Izvorni URL, za dostop obiščite https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594267/pdf/13014_2020_Article_1696.pdf
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Background: Expression of PD-L1 is the most investigated predictor of benefit from immune checkpoint blockade in advanced NSCLC but little is known about the association of PD-L1 expression and clinicopathological parameters of patients with unresectable stage III NSCLC. Methods: National registry data was searched for medical records of consecutive inoperable stage III NSCLC patients treated with ChT and RT from January 2012 to December 2017. Totally 249 patients were identified that met inclusion criteria and of those 117 patients had sufficient tissue for PD-L1 immunohistochemical staining. Results: Eighty patients (68.4%) expressed PD-L1 of >- 1% and 29.9% of more than 50%. Median PFS was 15.9 months in PD-L1 negative patients and 16.1 months in patients with PD-L1 expression >- 1% (p = 0.696). Median OS in PD-L1 negative patients was 29.9 months compared to 28.5 months in patients with PD-L1 expression >- (p = 0.888). There was no difference in median OS in patients with high PD-L1 expression (>- 50%) with 29.8 months compared to 29.9 months in those with low (1-49%) or no PD-L1 expression (p = 0.694). We found that patients who received a total dose of 60 Gy or more had significantly better median OS (32 months vs. 17.5 months, p < 0.001) as well as patients with PS 0 (33.2 vs. 20.3 months, p = 0.005). Conclusions: In our patients PD-L1 expression had no prognostic value regarding PFS and OS. Patients with good performance status and those who received a total radiation dose of more than 60 Gy had significantly better mOS.
Ključne besede:non small cell lung cancer, chemoradiotherapy, stage III
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Kraj izida:Velika Britanija
Založnik:Springer Nature
Leto izida:2020
Št. strani:str. 1-12
Številčenje:Vol. 15, no. 1
PID:20.500.12556/DiRROS-12619 Novo okno
UDK:616-006
ISSN pri članku:1748-717X
DOI:10.1186/s13014-020-01696-z Novo okno
COBISS.SI-ID:35740931 Novo okno
Avtorske pravice:© The Author(s) 2020.
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 5. 11. 2020; Članek št. 247;
Datum objave v DiRROS:09.11.2020
Število ogledov:1979
Število prenosov:1413
Metapodatki:XML DC-XML DC-RDF
:
VRANKAR, Martina, KERN, Izidor in STANIČ, Karmen, 2020, Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy. Radiation oncology [na spletu]. 2020. Vol. 15, no. 1, p. 1–12. [Dostopano 26 marec 2025]. DOI 10.1186/s13014-020-01696-z. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=12619
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiation oncology
Skrajšan naslov:Radiat. oncol.
Založnik:BioMed Central
ISSN:1748-717X
COBISS.SI-ID:3047444 Novo okno

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:29.10.2020

Sekundarni jezik

Jezik:Ni določen
Ključne besede:nedrobnocelični pljučni rak, kemoradioterapija, faza 3


Nazaj